ECE2022 Eposter Presentations Pituitary and Neuroendocrinology (211 abstracts)
Medical treatment of active acromegaly - the results from the Croatian Acromegaly Registry
Lana Sambula 1 , Mirsala Solak 2 , Ivana Kraljevic 2 , Hrvoje Popovac 2 , Tanja Skoric Polovina 2 , Karin Zibar Tomšić 2 , Tina Dusek 2 , Annemarie Balasko 2 & Darko Kastelan 2
1General Hospital Koprivnica, Department of Internal Medicine, Koprivnica, Croatia; 2University Hospital Centre Zagreb, Department of Endocrinology, Zagreb, Croatia
Background: The aim of this study was to evaluate the outcomes of medical treatment in patients with active acromegaly.
Material and Methods: We performed a retrospective analysis of 163 patients (101 female, age at diagnosis 47.2±13.4 years) treated between 1990 and 2020., of which 53 were on medical treatment (32.5%). Remission rate after pituitary surgery was 66.5% (n=105/158; 5 patients refused surgery). Patients who did not achieve remission and with relapse (n=2) underwent another surgery (n=18/60, 30%) and/or radiotherapy (n=33/60, 55%) and/or medical treatment (n=53/60, 88.3%). One patient refused further treatment after failed first pituitary surgery. The duration of follow-up was 115.8±304.4 months.
Results: Out of 53 patients on medical treatment, during follow-up monotherapy was used in 34 (64.2%) and combination therapy in 19 (35.8%) patients. Remission (IGF-1 < 1.2 ULN) was achieved in 51 patients (96.2%); in 21/53 (39.6%) with first generation somatostatin analogue (SSA-1) monotherapy, in 10/53 (18.9%) with dopamine agonist (DA) monotherapy, in one (1.9%) with pegvisomant monotherapy, in 13/53 (24.4%) with combination of SSA-1 and DA, in three (5.7%) with combination of SSA-1, DA and pegvisomant, in two (3.8%) patients with combination of SSA-2, DA and pegvisomant and in one (1.9%) after adding temozolomide on top of SSA-1 and DA. Two patients currently have active disease, both on SSA-1 monotherapy, of whom one is non-adherent to the tratment.
Conclusion: Our results indicate that medical treatment, when combined appropriately, can lead to biochemical remission in almost all patients with acromegaly.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more